|
NR. 2/2007
|
|
|
|
|
|
|
|
|
Zastosowanie
Avastinu (bewacyzumab) w leczeniu cukrzycowego obrzęku plamki
Avastin Use in the Diabetic Macular Oedema (DMO) Treatment
Małgorzata Zaraś, Anna Skłodowska,
Jerzy Szaflik
Katedra i Klinika Okulistyki II Wydziału Lekarskiego Akademii
Medycznej w Warszawie
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik |
|
|
|
|
|
|
|
| Summary: |
Diabetic retinopathy is
one of the serious complications of diabetes mellitus,
and leading cause of blindness. There are several
therapeutic options in the Diabetic Macular Oedema
treatment (pharmacotherapy, laser therapy, vitrectomy).
Recently new intravitreal drugs are used in the
treatment of eye diseases caused by increased level of
Vascular Endothelial Growth Factor (VEGF). Specific
inhibition of the angiogenic, vasoactive, and
permeability-inducing protein VEGF is possible by
Macugen, Lucentis and Avastin. Efficacy and safety of
intravitreally administered bevacizumab (Avastin), a
humanized monoclonal anti-VEGF agent have been assessed
in many off-label, short series trials, in AMD and
diabetic patients. Maintenance of the effect of
bevacizumab and its safety following repeated and
prolonged administration have to be investigated in
well-controlled studies. |
| |
|
| Key words: |
Diabetic Macular Oedema,
Diabetic retinopathy Angiogenesis, Laser therapy,
Vitrectomy, Bevacizumab. |
|
|
|
|
|
|
|
|
